Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
Provided By GlobeNewswire
Last update: Sep 27, 2024
First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models
MP0712 treatment leads to strong tumor growth inhibition with a good safety profile in vivo
Read more at globenewswire.comNASDAQ:MOLN (2/21/2025, 8:00:01 PM)
4.681
-0.23 (-4.75%)
Find more stocks in the Stock Screener
